文献速递神经介入DSAMR

Surpass Evolve血流导向装置治疗颅内动脉瘤的早期临床经验

Early clinical experience of using the Surpass Evolve flow diverter in the treatment of intracranial aneurysms.
PubMed 文献 · Neuroradiology · 2021-08-28

本研究比较了使用Surpass Evolve血流导向装置(SE组31例)与其他商业血流导向装置(对照组53例)治疗颅内动脉瘤的早期经验。SE组技术失败3例(9.7%),主要并发症4例(12.9%),术后MRI DWI阳性病灶3例(9.7%)。多因素调整后,SE组与较短手术时间(≥90分钟)、球囊扩张及DWI阳性病灶独立相关。结论认为SE安全且易于释放。

要点

  • SE组技术失败率9.7%,主要并发症率12.9%,需关注支架贴壁不良和移位。
  • SE组术后DWI阳性病灶率9.7%,多因素显示SE与DWI阳性病灶独立负相关。
  • SE组球囊扩张使用率25.8%,多因素显示SE与球囊扩张独立负相关。

诊断标准与关键数值

  • SE组技术失败3例(9.7%),包括贴壁不全1例(3.2%)和支架移位2例(6.5%)。
  • SE组主要并发症4例(12.9%):靶动脉瘤延迟破裂、大缺血性卒中、不明原因猝死、载瘤动脉闭塞伴支架血栓各1例(3.2%)。
  • SE组球囊扩张8例(25.8%),术后MRI DWI阳性病灶3例(9.7%)。
  • 多因素调整后,SE组与手术时间≥90分钟独立相关(调整OR 0.09,95%CI 0.03-0.29,p<0.001)。
  • SE组与球囊扩张独立相关(调整OR 0.22,95%CI 0.07-0.75,p=0.015),与DWI阳性病灶独立相关(调整OR 0.04,95%CI 0.01-0.19,p<0.001)。

临床应用与阅片要点

  • 使用SE装置时需注意支架贴壁和移位风险,必要时球囊扩张辅助。
  • 术后MRI DWI可用于检测无症状缺血性病灶,SE组发生率较低。

局限性

  • 单中心回顾性研究,样本量较小,SE组仅31例。
  • 对照组使用两种不同血流导向装置,可能存在异质性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: Here, we presented our early experience with flow diversion procedures using the Surpass Evolve flow diverter (SE, Stryker) and reported the feasibility and safety profile compared to those of a control group treated with other types of flow diverters.

METHODS: We included 31 and 53 consecutive flow diversion procedures performed using the SE and other commercial flow diverters, respectively, to treat intracranial aneurysms at our institution. We used two commercial flow diversion systems in the comparison group: the pipeline embolization device and Surpass Streamline.

RESULTS: In the SE group, technical failures occurred in three (9.7%) cases, due to either incomplete wall apposition (n = 1, 3.2%) or stent migration (n = 2, 6.5%). Major complications occurred in four (12.9%) cases: delayed rupture of the target aneurysm (n = 1, 3.2%), major ischemic stroke (n = 1, 3.2%), sudden death from an unidentified cause (n = 1, 3.2%), and parent artery occlusion with stent thrombosis (n = 1, 3.2%). Balloon angioplasty was performed in eight (25.8%) cases. On post-procedure MRI, a DWI-positive lesion was detected in three (9.7%) cases. After multivariate adjustment, the SE group was independently associated with less procedural time of ≥ 90 min (adjusted OR, 0.09; 95% CI, 0.03-0.29; p < 0.001), balloon angioplasty (adjusted OR, 0.22; 95% CI, 0.07-0.75; p = 0.015), and DWI-positive lesions (adjusted OR, 0.04; 95% CI, 0.01-0.19; p < 0.001).

CONCLUSION: The SE is safe and easy to deploy.

来源:Neuroradiology,查看原文。版权归原作者所有。

引用

  1. Jee TK, Yeon JY, Kim KH, et al. Early clinical experience of using the Surpass Evolve flow diverter in the treatment of intracranial aneurysms. Neuroradiology. 2021. PMID: 34453182. doi:10.1007/s00234-021-02793-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。